Walk-In Interview for QA, Q.C. Manufacturing, Eng.Jobs in USV Pvt Ltd on 8th may
In India we are recognized for our leadership in the
Oral Anti-Diabetic market where we rank No. 1 by Rx and Value. In the
Cardiovascular diseases segment we are No. 1 by Rx and in the top 8 by
Value. We also have a significant presence in the areas of Vitamins,
Minerals, Nutrients, Dermatology, Gastroenterology and CNS.
We are 2000 carore health care company with operations in India, US &
EU, with leadership in diabetes and cardiovascular segments. We provide a
supportive and learning, environment where personal growth is
encouraged and nurtured. We have three plants based at Daman and Baddi
manufacturing Tablets, Capsules: Sterile injectables & Ophthalmic
Products, one API plant at Chiplun and biotechnology facility in Nerul
Mumbai. All our plants are approved by US, EU, Health Canada and other
leading country's regulators
here is I am giving information about Interview on 8th may
Dear Candidate,
We have scheduled Walk-In for USV Pvt Ltd., Daman Plant on 8th May, 2016 (Sunday)
INTERVIEW VENUE:
USV Pvt Ltd.-Daman Plant
Date: 8th May, 2016 - SUNDAY
TIME: 10:00 AM to 04:00 PM
Job Location: Daman
Vacancy for Different Areas are:
- Quality Control
- Quality Assurance
- Manufacturing
- Engineering
Candidates may Walk-In for an interview along with their updated Resume,updated salary slip
Regards,
Ajeet Singh
Human Resources
USV Pvt Ltd.
Office no: 02606636229/232
Great Place To Work
Value addition at all levels of the organisation chain
is essential and necessary for the growth and success of our company. To
ensure this, USV provides an environment that:
- Values people
- Promotes learning
- Nurtures innovation
- Rewards collective excellence
About USV
We are a 53 year old leading healthcare company which
began as a joint venture with USV&P Inc. USA, a subsidiary of
Revlon. Our product offering today includes Active Pharmaceutical
Ingredients (APIs), Fixed Dosages Formulations (FDF), Peptides,
Biosimilars and Injectables. These are manufactured in our cGMP
compliant plants located in India.
We market our products globally to 75 countries. In the
financial year 2013-14, our total income was Rs. 20,099 million. Our
Indian business contributed 78% to the revenue and the rest was from
export of APIs and Finished Dosages.
Our international business consists of:
- A large portfolio of small molecule APIs. Of the 52 products in our portfolio, 27 APIs are commercially available, while others are in various stages of development. Our special skills include production and characterization of polymorphs and particle sizing
- A portfolio of Finished Dosages. These include immediate release, modified release and products with 'complex' characteristics which are promoted through ANDA filings and Dossiers linked to supply.
Our spend of 7.35% of sales on R&D ensures that we
are able to deliver on our research portfolio. We have over 100,000 sq.
ft. of laboratory space with excellent infrastructure. Our research is
driven by a team of 262 scientists including 2 doctors, 31 PhDs and 229
post-graduates, many of whom have studied in universities in USA, Europe
and Japan. Our intellectual property portfolio consists of patent
filings for 43 inventions of which 18 have been granted.
Comments
Post a Comment